DEERFIELD MANAGEMENT COMPANY, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001009258

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2025 · 119 positions · Total reported value $5.12B · Top-10 concentration 57.4% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.6% · 10 new · 12 cut · 12 exited

Active Share (vs S&P 500): 99.6% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +17.1% · vs SPY +2.2% · Prev Value $7.59B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2025 13F filing, DEERFIELD MANAGEMENT COMPANY, L.P. disclosed 119 equity positions with a combined reported value of $5.12B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 57.4% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2025 were NUVL ($1.37B), OSCR ($249.77M), VTRS ($214.53M). By sector, the heaviest allocations are Health Care 63.8%, Industrials 1.1%. Versus the prior quarter, allocation shifted toward Health Care (+3.2pp) and away from Other (-3.6pp).

Versus the prior quarter, DEERFIELD MANAGEMENT COMPANY, L.P. opened 10 new positions, trimmed 12 and fully exited 12, a turnover rate of 38.6% of positions. The portfolio's overlap with the prior quarter was 46% of names.

The largest new positions opened in Q2 2025 were MRK ($67.90M), TNDM ($38.52M), MRNA ($27.59M).

Of the 12 positions fully exited versus the prior quarter, the largest were DVAX ($67.33M), CMRX ($32.09M), INMD ($28.01M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2025)

  • MRK MERCK & CO. INC. · $67.90M
  • TNDM TANDEM DIABETES · $38.52M
  • MRNA MODERNA INC · $27.59M
  • LIVN LIVANOVA PLC · $25.40M
  • VTR VENTAS INC · $22.36M
  • INSP INSPIRE MED SYS INC COM · $18.17M
  • XENE XENON PHARMACEUTICALS INC · $16.97M
  • VCYT VERACYTE INC · $16.89M

Fully Exited (vs previous quarter)

  • DVAX DYNAVAX TECHNOLOGIES CORP · prev qtr: $67.33M
  • CMRX CHIMERIX INC · prev qtr: $32.09M
  • INMD INMODE LTD · prev qtr: $28.01M
  • LNTH LANTHEUS HLDGS INC · prev qtr: $23.45M · history
  • CGON CG ONCOLOGY INC · prev qtr: $20.83M
  • ESTA ESTABLISHMENT LABS HLDGS INC · prev qtr: $20.40M
  • BEAM BEAM THERAPEUTICS INC · prev qtr: $17.14M
  • CON CONCENTRA GROUP HOLDINGS PAREN COMMON STOCK · prev qtr: $14.11M

Insider Transactions (Form 4)

Latest DEERFIELD MANAGEMENT COMPANY, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-07-15 D Nuvalent, Inc. 3,444 $124.00 SEC filing
2026-07-15 U Nuvalent, Inc. 5,146 $124.00 SEC filing
2026-07-15 D Nuvalent, Inc. 650,000 $124.00 SEC filing
2026-07-15 D Nuvalent, Inc. 8,299,225 $124.00 SEC filing
2026-06-16 Award Nuvalent, Inc. 3,444 — SEC filing
2026-06-11 Conversion Parabilis Medicines, Inc. 407,132 — SEC filing
2026-06-11 Conversion Parabilis Medicines, Inc. 260,992 — SEC filing
2026-06-11 Conversion Parabilis Medicines, Inc. 149,238 — SEC filing

All insider transactions →

Fund Profile

Deerfield Management Company, L.P. is a New York-based hedge fund founded by Marianne and James Chadwin, known for its quantitative and fundamental research approach focused primarily on healthcare and biotechnology investments.

Investment Approach

Combines quantitative analysis with fundamental research

Specializes in healthcare and biotechnology sectors

Utilizes both public and private investment strategies

Asset Classes & Strategy

Primarily focused on long/short equity positions

Specializes in healthcare and biotechnology investments

Also invests in other sectors with strong fundamental research

Key Personnel

Marianne Chadwin (Co-founder)

James Chadwin (Co-founder)

Team of experienced portfolio managers and researchers

AUM & Performance

Manages approximately $19.1 billion in assets under management

Performance data not publicly disclosed

All information is based on publicly available SEC filings and company disclosures.

Sector Allocation

Health Care 63.8%
Technology 1.0%
Materials 0.0%
Financials 0.0%
Other 33.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 17.99M $1.37B 26.82%
26.82%
Hold
2 11.65M $249.77M 4.88%
4.88%
Reduce
3 24.02M $214.53M 4.19%
4.19%
Hold
4 3.38M $178.03M 3.48%
3.48%
Add
5 3.19M $172.90M 3.38%
3.38%
Add
6 9.72M $169.69M 3.32%
3.32%
Reduce
7 10.57M $155.76M 3.04%
3.04%
Hold
8 540.63K $155.35M 3.04%
3.04%
Add
9 1.17M $146.78M 2.87%
2.87%
Reduce
10 3.38M $124.50M 2.43%
2.43%
Add
11 70.00M $124.21M 2.43%
2.43%
Hold
12 15.36M $106.92M 2.09%
2.09%
Reduce
13 2.96M $105.13M 2.05%
2.05%
Add
14 4.31M $104.38M 2.04%
2.04%
Add
15 9.90M $93.40M 1.82%
1.82%
Add
16 5.12M $92.65M 1.81%
1.81%
Add
17 3.92M $82.30M 1.61%
1.61%
Add
18 3.35M $78.88M 1.54%
1.54%
Add
19 700.70K $70.52M 1.38%
1.38%
Add
20 857.72K $67.90M 1.33%
1.33%
New
21 2.88M $62.48M 1.22%
1.22%
Reduce
22 21.23M $61.36M 1.20%
1.20%
Hold
23 1.92M $58.23M 1.14%
1.14%
Hold
24 226.07K $54.56M 1.07%
1.07%
Hold
25 919.40K $48.69M 0.95%
0.95%
Add
26 145.00K $47.28M 0.92%
0.92%
Hold
27 4.78M $46.08M 0.90%
0.90%
Reduce
28 3.93M $45.94M 0.90%
0.90%
Add
29 2.22M $43.30M 0.85%
0.85%
Add
30 4.69M $42.04M 0.82%
0.82%
Reduce
31 40.00M $38.52M 0.75%
0.75%
New
32 700.27K $36.47M 0.71%
0.71%
Add
33 2.02M $35.51M 0.69%
0.69%
Hold
34 3.86M $29.03M 0.57%
0.57%
Hold
35 686.93K $28.89M 0.56%
0.56%
Add
36 1.01M $28.87M 0.56%
0.56%
Hold
37 653.00K $28.50M 0.56%
0.56%
Add
38 1.00M $27.59M 0.54%
0.54%
New
39 2.07M $27.10M 0.53%
0.53%
Reduce
40 2.75M $26.64M 0.52%
0.52%
Add
41 25.00M $25.40M 0.50%
0.50%
New
42 3.72M $24.20M 0.47%
0.47%
Add
43 354.00K $22.36M 0.44%
0.44%
New
44 1.62M $20.15M 0.39%
0.39%
Hold
45 2.64M $18.96M 0.37%
0.37%
Hold
46 6.71M $18.19M 0.35%
0.35%
Hold
47 140.00K $18.17M 0.35%
0.35%
New
48 7.96M $18.16M 0.35%
0.35%
Hold
49 1.17M $17.01M 0.33%
0.33%
Add
50 542.02K $16.97M 0.33%
0.33%
New

FAQ

What did DEERFIELD MANAGEMENT COMPANY, L.P. buy in 2025-Q2?

In its 2025-Q2 13F filing, DEERFIELD MANAGEMENT COMPANY, L.P. reported 119 equity positions worth $5.12B in aggregate; its largest disclosed positions were NUVL ($1.37B), OSCR ($249.77M), VTRS ($214.53M).

How large is DEERFIELD MANAGEMENT COMPANY, L.P.'s portfolio?

DEERFIELD MANAGEMENT COMPANY, L.P. reported $5.12B of long equity holdings across 119 positions as of 2025-Q2. Top-10 holdings account for 57.4% of reported value.

What is DEERFIELD MANAGEMENT COMPANY, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/deerfield-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →